fbpx

ESA News Highlights

COVID19

The Lancet: Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine. The two-part vaccine included two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S)
In the phase 1 part of each trial, the individual components of the two-part vaccine (rAd26-S and rAd5-S) were tested for safety. The phase 2 study then tested whether…

Latest news

Welcome to the new EJA Editor-in-Chief

The ESA is very happy to welcome aboard our newest Editor-in-Chief (EIC) for the European Journal of Anaesthesiology (EJA), Charles Marc Samama. His role officially started on 14 September 2020. Char...

ESA will become ESAIC

We are proud to announce that, as of 1 October 2020, the European Society of Anaesthesiology will officially become the European Society of Anaesthesiology and Intensive Care. The ESA has a proven...

A message from the ESA Presidents

The COVID-19 pandemic, a global phenomenon, is leading to an unprecedented loss of life in the EU union while putting great stress on the healthcare systems due to the fast spread of the virus and the...